Gefitinib

Gefitinib is an oral medication belonging to a class of drugs called epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. It is primarily used for the treatment of certain types of non-small cell lung cancer (NSCLC) that have tested positive for EGFR mutations. These mutations are responsible for the uncontrolled growth and spread of cancer cells.
Gefitinib works by inhibiting the EGFR protein, which is found on the surface of cancer cells and plays a crucial role in cell growth and division. By blocking the EGFR protein, gefitinib prevents the cancer cells from receiving signals to grow and divide, thereby slowing down the progression of the disease.
The medication is typically prescribed for patients with advanced or metastatic NSCLC who have not responded well to other treatments or whose cancer has progressed after receiving chemotherapy. It is also used as a first-line treatment for patients with early-stage NSCLC that is not suitable for surgery or radiation therapy due to the presence of EGFR mutations.
Gefitinib is available in tablet form and is usually taken once daily. The most common side effects of gefitinib include skin rash, diarrhea, and mouth sores. Patients should consult their healthcare provider if they experience any side effects that are severe or persistent.